19 March 2025 in Molecular Cancer
Ovarian cancer is a gynecological malignancy with the highest recurrence and mortality rates. Although niraparib can effectively affect its progression, the challenge of drug resistance remains. Herein, niraparib-resistant ovarian cancer cell lines were constructed to identify the abnormally activated enhancers and associated target genes via RNA in situ conformation sequencing. Notably, the target gene RAD23A was markedly upregulated in niraparib-resistant cells, and inhibiting RAD23A restored their sensitivity. Additionally, abnormal activation of glycolysis in niraparib-resistant cells induced lactate accumulation, which promoted the lactylation of histone H4K12 lysine residues. Correlation analysis showed that key glycolysis enzymes such as pyruvate kinase M and lactate dehydrogenase A were significantly positively correlated with RAD23A expression in ovarian cancer. Additionally, H4K12la activated the super-enhancer (SE) of niraparib and RAD23A expression via MYC transcription factor, thereby enhancing the DNA damage repair ability and promoting the drug resistance of ovarian cancer cells. Overall, the findings of this study indicate that lactic acid accumulation leads to lactylation of histone H4K12la, thereby upregulating SE-mediated abnormal RAD23A expression and promoting niraparib resistance in ovarian cancer cells, suggesting RAD23A as a potential therapeutic target for niraparib-resistant ovarian cancer.
17 September 2025 in Materials Today Bio
Ovarian cancer progression is closely associated with tumor microenvironment (TME) dysregulation, particularly pathological angiogenesis driven by exosome-mediated crosstalk. Here, we elucidate that ovarian cancer-derived circPUM1 promotes angiogenesis by transferring to vascular endothelial cells via exosomes. Mechanistically, circPUM1 upregulates the expression of RAB27B and VEGFA by sponging miR-607, thus boosting release of exosome facilitated by RAB27B and directly activating VEGF signaling in endothelial cells to foster angiogenesis. To disrupt this circPUM1-driven TME modulation, we engineered an innovative pH-responsive 2D niobium carbide nanosheets loaded with circPUM1 siRNA. Through excessive PEI grafting, we functionalized the nanosheets with cationic property, achieving efficient negative-charged siRNA loading. Further surface PEGylation shielded the nanosheets’ positive charge, reducing off-target effect and systemic toxicity, while acidic TME triggered PEG exfoliation for tumor-specific circPUM1 siRNA delivery. Functional cellular assays and an intraperitoneal tumor-bearing mouse model validated that the nanosheet-delivered circPUM1 siRNA effectively inhibited angiogenesis and peritoneal dissemination by knocking down circPUM1 expression and subsequently downregulating its downstream targets. This study uncovers a novel exosome-mediated angiogenesis mechanism and develops innovative MXene nanosheets for pH-responsive siRNA delivery providing a promising strategy for ovarian cancer precision therapy with significant clinical translational value and application potential.
6 February 2026 in Science Advances
Thrombotic disorders remain among the leading causes of global mortality, yet current thrombolytic therapies are limited by poor targeting specificity and inadequate microenvironmental modulation, resulting in suboptimal efficacy and serious side effects. Here, we developed a hydrogen-generating nanothrombolytic agent that enables enzymatic clot dissolution in combination with intelligent microenvironment reprogramming. Specifically, we assembled urokinase, a clinical thrombolytic drug, with hydrogenated silicene (SiH) nanosheet and fibrinogen, a substrate of coagulation reaction, to promote thrombolysis. Functionally, SiH nanosheet plays multiple roles in the nanothrombolytics: blocking the functional sites of urokinase to durably inhibit its activity in circulation to prevent systemic bleeding, followed by urokinase reactivation in response to SiH nanosheet self-degradation and prothrombotic microenvironment regulation through the in situ hydrogen generation, which mitigates the oxidative stress of vascular endothelial cells and inhibits their release of procoagulant factors. This microenvironment-adaptive thrombolysis strategy offers a promising paradigm for the precise management of thrombotic emergencies.